The FDA has cleared a new, first-in-class medication for attention-deficit/hyperactivity disorder that works through a novel mechanism. The drug, classified as an NDSRI, is now an option for both adults and children, marking a major shift in ADHD treatment choices. Providers and patients are weighing how this new therapy fits …